Availability of Misoprostol
There are currently multiple dedicated Misoprostol products on the global medication market. A list and detailed map can be accessed by clicking the link below
Off -Label Use
Misoprostol is currently only approved by the Food and Drug Administration (FDA) for the prevention and treatment of gastric ulcers resulting from chronic administration of nonsteroidal anti-inflammatory drugs (NSAIDS)
Use of misoprostol in obstetrics and gynaecology. The correct dosage varies greatly according to gestation, indication and route of administration - using the correct dosage is vital for success and to prevent complications.
Angusta®, tablet of 25 µg misoprostol for oral induction of labour approved for marketing in the Nordic countries
In March 2017, the Danish pharmaceutical company, Azanta A/S obtained
Misoprostol exposure during the first trimester of pregnancy: Is the malformation risk varying depending on the indication?
European Journal of Obstetrics & Gynecology and Reproductive Biology published
Misoprostol ‘Snakes and Ladders’ game
Shanice Richardson, a University of Liverpool medical student, has produced
This page contains links to key international organisations who promote the safe and effective use of misoprostol, with a focus on the needs of women in low resource settings.
Misoprostol, like the vast majority of drugs, has potential adverse effects. The Summary of Product Characteristics (SPC) for Cytotec lists the potential problems - link here for more details, and for ways of avoiding complications.